Controlled Release Vaccines and Methods of Treating Brucella Diseases and Disorders
AssigneeThe Texas A&M University System
InventorsThomas A. Ficht, Allison Ficht, Renee Tsolis, Leslie Garry Adams
Life of this patent
Estimating the term…
Abstract
Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
Claims20
A vaccine composition comprising:
- a Brucella strain comprising one or more attenuating gene knockouts and further comprising a diagnostic gene knockout;
- and
- an encapsulating agent comprising vitelline protein B capable of releasing the Brucella strain at a predetermined rate.
A method for evaluating efficacy of a vaccine against brucellosis in an animal subject comprising the steps of:
- providing a vaccine comprising:
- a single or a double mutant strain of Brucella comprising one or more attenuating gene knockouts and further comprising a diagnostic gene knockout, wherein the attenuating gene knockouts comprise ΔmucR, ΔvjbR, ΔvirB2, ΔmanB/A, ΔvirB2/ΔmanB/A mutant, ΔvjbR/ΔmucR mutant, ΔvirB2/ΔmucR mutant, ΔvirB2/ΔvjbR mutant, ΔvjbR/ΔmanB/A mutant, ΔmucR/ΔmanB/A mutant, or any combinations thereof, wherein the diagnostic gene knockout comprises a differentiation of infected animals from vaccinated animals (DIVA) mutant that includes ΔvirB12, Δbcsp31, Δasp24, or any combinations thereof;
- and
- an encapsulating agent comprising vitelline protein B capable of releasing the Brucella strain at a predetermined rate;
- inoculating the animal subject with the vaccine;
- providing one or more animal subjects suffering from brucellosis or naturally infected with the Brucella strain;
- performing a DIVA assay based on a diagnostic or serological test to differentiate detection of one or more antibodies against the one or more attenuating gene knockouts in the infected and the vaccinated animal subjects;
- and
- evaluating efficacy of the vaccine against brucellosis based on a presence or absence of the one or more antibodies against the one or more attenuating gene knockouts.
A method for prophylaxis, amelioration of symptoms, or any combinations thereof against brucellosis in a human or animal subject comprising the steps of:
- identifying the human or animal subject in need of the prophylaxis, amelioration of symptoms, or any combinations thereof against brucellosis;
- and
- administering a therapeutically effective amount of a vaccine composition to the human or animal subject for the prophylaxis, amelioration of symptoms, or any combinations thereof against brucellosis, wherein the vaccine comprises:
- a Brucella strain comprising one or more attenuating gene knockouts and further comprising a diagnostic gene knockout;
- an encapsulating agent comprising vitelline protein B capable of releasing the Brucella strain at a predetermined rate;
- and
- an optional adjuvant or a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.